Showing results (331-340 of 342) with videos related to

Sort By:
Pageof 35
Journal of Acquired Immune Deficiency Syndromes (1999)|July 11, 2009
Effects of a rapid peer-based HIV/AIDS educational intervention on knowledge and attitudes of high school students in a high-income Arab countryPeter Barss, Michal Grivna, Maria Ganczak, et al.
Journal of Alzheimer'S Disease : JAD|April 26, 2018
The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down SyndromeAlain D Dekker, Silvia Sacco, Angelo Carfi, et al.
Terapevticheskii Arkhiv|October 26, 2022
[Prevalence and prognostic value of gastroenterological manifestations of COVID-19: data from the Russian University Clinic]O O Ianushevich, I V Maev, N I Krikheli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2020
Multidose Priming and Delayed Boosting Improve Plasmodium falciparum Sporozoite Vaccine Efficacy Against Heterologous P. falciparum Controlled Human Malaria InfectionKirsten E Lyke, Alexandra Singer, Andrea A Berry, et al.
Malaria Journal|July 25, 2016
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicityBradley W Hickey, Joanne M Lumsden, Sharina Reyes, et al.
Human Vaccines & Immunotherapeutics|August 1, 2013
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infectionCindy Tamminga, Martha Sedegah, Santina Maiolatesi, et al.
Plos One|June 20, 2020
IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagentsBradley Hickey, Nimfa Teneza-Mora, Joanne Lumsden, et al.
The Lancet Regional Health. Western Pacific|February 6, 2026
Towards equitable cancer outcomes for rural and remote communities: reflections, lessons and recommendationsAnna Ugalde, Hannah Jongebloed, Charlene Wright, et al.
Plos One|October 18, 2011
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentCindy Tamminga, Martha Sedegah, David Regis, et al.
Plos One|September 8, 2021
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adultsMarvin J Sklar, Santina Maiolatesi, Noelle Patterson, et al.
Pageof 35